SCHEMBL136106

SCHEMBL136106

O=C(O)C(=O)N1CCC(Cc2ccc(F)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
POLB P06746 1/20 0.59
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
MAPK14 Q16539 1/20 0.55
KDM4E B2RXH2 1/20 0.54
ALDH1A1 P00352 1/20 0.54
MAPT P10636 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2925616 0.89 MEN1 (0.60) MEN1KMT2APOLBCYP2C9CYP2C19
SCHEMBL21614171 0.88 MEN1 (0.53) MEN1KMT2APOLBGRIN2DGRIN3B
SCHEMBL19994627 0.87 MEN1 (0.55) MEN1KMT2APOLBCYP2C9CYP2C19
SCHEMBL14559864 0.86 MEN1 (0.56) MEN1KMT2APOLBCYP2C9CYP2C19
SCHEMBL4576736 0.85 L3MBTL1 (0.69) MEN1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL16600135 0.84 MEN1 (0.55) MEN1KMT2APOLBGRIN2DGRIN3B
SCHEMBL1761030 0.84 MEN1 (0.55) MEN1KMT2APOLBCYP2C9CYP2C19
SCHEMBL4578422 0.84 ALDH1A1 (0.57) MEN1KMT2AGRIN2DGRIN3BGRIN1
SCHEMBL5806708 0.84 MEN1 (0.55) MEN1KMT2APOLBGRIN2DGRIN3B
SCHEMBL4576966 0.84 FAAH (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053786-A1 FORMULATIONS OF RADIPRODIL GRIN THERAPEUTICS INC (US) 2026-02-26 US disclosed
US-12419881-B1 Methods of using radiprodil in the treatment of disorders GRIN THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250288574-A1 METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS GRIN THERAPEUTICS, INC. 2025-09-18 US disclosed
US-20250288518-A1 METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS GRIN THERAPEUTICS, INC. 2025-09-18 US disclosed
US-20250127770-A1 FORMULATIONS OF RADIPRODIL GRIN THERAPEUTICS, INC. 2025-04-24 US disclosed
US-20120059034-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION RICHTER GEDEON NYRT. (HU) 2012-03-08 US disclosed
EP-2403850-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION Richter Gedeon Nyrt. (HU) 2012-01-11 EP disclosed
EP-2303014-A1 NOVEL CRYSTALLINE FORM OF 2-Ý4(4-FLUORO-BENZYL)-PIPERIDINE-1-YL¨-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE Richter Gedeon Nyrt. (HU) 2011-04-06 EP disclosed
WO-2010100512-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEM PREPARATION RICHTER GEDEON NYRT. (HU) 2010-09-10 WO disclosed
US-20100010044-A1 NOVEL CRYSTALLINE FORM OF 2-[4-(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-01-14 US disclosed
WO-2010006020-A1 NOVEL CRYSTALLINE FORM OF 2-[4(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2010-01-14 WO disclosed
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US disclosed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP disclosed
CN-100413860-C piperidine derivatives as NMDA receptor antagonists HUNGARY GIREL GYOGYSZERGYAR (HU) 2008-08-27 CN disclosed
CN-1556805-A piperidine derivatives as NMDA receptor antagonists ������ҩ�����޹�˾ 2004-12-22 CN disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US disclosed
EP-1409477-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2004-04-21 EP disclosed
WO-2003010159-A1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS Richter Gedeon Vegyészeti Gyár Rt. (HU) 2003-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260053786-A1 FORMULATIONS OF RADIPRODIL GRIN2D, GRIN2A, GRIN2B MEN1 2042/4885KMT2A 1298/4885POLB 4671/4885
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C MEN1 2584/4885KMT2A 1234/4885POLB 3167/4885
US-20250288574-A1 METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS CLN6, GABARAPL2, GABARAPL1 MEN1 1864/4885KMT2A 3960/4885POLB 1720/4885
US-20100010044-A1 NOVEL CRYSTALLINE FORM OF 2-[4-(4-FLUORO-BENZYL)-PIPERIDINE-1-YL]-2-OXO-N-(2-OXO-2,3-DIHYDRO-BENZOXAZOL-6-YL)-ACETAMIDE UACA, CANX, AQP4 MEN1 4351/4885KMT2A 1130/4885POLB 2533/4885
US-12419881-B1 Methods of using radiprodil in the treatment of disorders CLN6, GABARAPL2, GABARAPL1 MEN1 1864/4885KMT2A 3960/4885POLB 1720/4885
US-20120059034-A1 NOVEL CRYSTALLINE HYDRATE, AMORPHOUS AND POLYMORPHIC FORMS OF DIHYDRO-BENZOXAZOLE-6-YL-ACETAMIDE DERIVATIVE AND PROCESSES FOR THEIR PREPARATION DHX35, DHX9, ABCG2 MEN1 4684/4885KMT2A 3952/4885POLB 2702/4885
US-20250288518-A1 METHODS OF USING RADIPRODIL IN THE TREATMENT OF DISORDERS CLN6, GABARAPL2, GABARAPL1 MEN1 1864/4885KMT2A 3960/4885POLB 1720/4885
US-20250127770-A1 FORMULATIONS OF RADIPRODIL GABARAPL2, PARL, GABARAPL1 MEN1 2922/4885KMT2A 4623/4885POLB 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.